2019 American Transplant Congress
Evolution of HHV6- and CMV-Specific T Cell Functional Responses and Immune Cell Populations after Kidney Transplant
*Purpose: Human herpesvirus (HHV)-6 reactivation after solid organ or hematopoietic stem cell transplant has been associated with complications such as graft rejection and all-cause mortality.…2019 American Transplant Congress
TACI Polymorphisms Associated with Increased Alloimmunity and Allograft Rejection
*Purpose: Transmembrane activator and CAML interactor (TACI) controls B cell differentiation. The TACI gene is highly polymorphic (>95% of all genes) and frequently variants exhibit…2019 American Transplant Congress
Examination of a Novel Immunoregulatory Marker in Kidney and Lung Transplant Recipients
*Purpose: The T-cell immunoglobulin and immunoreceptor tyrosine-based inhibitory motif domain (TIGIT) is a co-inhibitory receptor mainly expressed on T cells and NK cells. TIGIT has…2019 American Transplant Congress
Immunologically Tolerant Liver Transplant Recipients Are Characterized by Donor-Specific Hypo Responsiveness of Circulating T-cells
*Purpose: Lifelong treatment with immunosuppressive drugs (IS) to prevent graft rejection in transplant recipients is accompanied by side effects. Some recipients are considered to be…2019 American Transplant Congress
Impact of Cytomegalovirus on the Immune System of Healthy Humans
Emory Transplant Center, Emory University, Atlanta, GA
*Purpose: CMV is a frequent pathogen after transplantation. 2/3 of recipients harbor latent CMV and are at moderate risk. CMV- recipients divide into high or…2019 American Transplant Congress
Differences in CMV-Specific CD4 T Cell Population in De Novo Kidney Transplant Recipients Treated with Everolimus-Based Regimen Compared to a Standard Tacrolimus-MPA Regimen: Results from ATHENA
1ATHENA, CMV Substudy Group, Germany, 2Novartis, Pharma GmbH, Germany
*Purpose: The ATHENA trial was designed to compare everolimus [EVR] in combination with tacrolimus [TAC] or cyclosporine A [CyA] vs. a standard regimen of mycophenolic…2019 American Transplant Congress
Comparison with Solid Organ Transplants Reveals Distinct Face Transplant Rejection Gene Signature That Reflects the Unique Immunobiology of Skin
Brigham and Women's Hospital, Boston, MA
*Purpose: Skin containing transplants, such as face transplants, are immunologically unique. We compared the gene expression profiles of acute cellular rejection in human face transplants…2019 American Transplant Congress
Peripheral Blood Regulatory T Cells In The Folow In The Kidney-transplant Patients
*Purpose: Investigate the peripheral blood levels of CD4+CD25+FOXP3p3+ regulatory T cells (Tregs) in patients with kidney transplant at least one year after kidney transplantation and…2019 American Transplant Congress
Deficiency of the Transcription Factor Satb1 in T Cells Promotes Solid Organ Allograft Survival
*Purpose: Conventional CD4+ T cells are key effectors of allograft rejection and novel therapies limiting their response may hold promise in the context of organ…2018 American Transplant Congress
Metabolic Therapy as a Platform for CTLA4Ig Costimulation Blockade in Preventing Allograft Rejection
The backbone of current immunosuppression regimens remains calcineurin inhibitors (CNI) in association with steroids, mycophenolate mofetil or mTOR inhibitors. However, their long-term administration is associated…
- « Previous Page
- 1
- …
- 24
- 25
- 26
- 27
- 28
- …
- 53
- Next Page »